Financial Ratios Northwest Biotherapeutics, Inc. Börse Stuttgart
Stocks
NBYB
US66737P6007
Biotechnology & Medical Research
|
Delayed
Börse Stuttgart
12:48:19 2026-08-27 EDT
|
5-day change | 1st Jan Change | ||
| 0.1510 EUR | 0.00% |
|
+0.67% | -26.70% |
| Fiscal Period: December | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -90.17 | -117.48 | -117.23 | -152.28 | -69.33 | |||||
Return on Total Capital | 15.35 | 50.94 | 86.42 | 637.78 | -1.31K | |||||
Return On Equity % | -73.57 | 91.72 | 82.31 | 132.94 | 95.08 | |||||
Return on Common Equity | -73.57 | 83.33 | 66.41 | 106.32 | 79.44 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | -2.01K | -1.34K | -2.42K | -1.99K | |||||
SG&A Margin | 3.32K | 1.98K | 1.54K | 2.39K | 2.36K | |||||
EBITDA Margin % | -5.21K | -3.92K | -2.79K | -4.69K | -4.2K | |||||
EBITA Margin % | -5.24K | -3.99K | -2.87K | -4.81K | -4.34K | |||||
EBIT Margin % | -5.24K | -3.99K | -2.87K | -4.81K | -4.35K | |||||
Income From Continuing Operations Margin % | 17.82K | -6.24K | -3.24K | -6.06K | -4.37K | |||||
Net Income Margin % | 17.82K | -6.24K | -3.24K | -6.06K | -4.37K | |||||
Net Avail. For Common Margin % | 17.82K | -6.24K | -3.33K | -6.16K | -4.46K | |||||
Normalized Net Income Margin | 11.15K | -3.8K | -1.85K | -3.45K | -2.91K | |||||
Levered Free Cash Flow Margin | -26.87K | -2.88K | -6.11K | -2.18K | -1.74K | |||||
Unlevered Free Cash Flow Margin | -26.78K | -2.82K | -6.07K | -2.01K | -1.48K | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.03 | 0.05 | 0.07 | 0.05 | 0.03 | |||||
Fixed Assets Turnover | 0.06 | 0.09 | 0.09 | 0.07 | 0.07 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.13 | 0.07 | 0.09 | 0.06 | 0.06 | |||||
Quick Ratio | 0.11 | 0.06 | 0.05 | 0.03 | 0.03 | |||||
Operating Cash Flow to Current Liabilities | -0.29 | -0.42 | -1.19 | -0.84 | -0.49 | |||||
Average Days Payable Outstanding | - | 90.77 | 137.75 | 142.74 | 302.96 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -30.6 | -24.99 | -96.82 | -85.39 | -136.28 | |||||
Total Debt / Total Capital | -44.09 | -33.32 | -3.05K | -584.4 | 375.66 | |||||
LT Debt/Equity | -24.5 | -9.86 | -52.63 | -41.45 | -46.86 | |||||
Long-Term Debt / Total Capital | -35.31 | -13.15 | -1.66K | -283.66 | 129.16 | |||||
Total Liabilities / Total Assets | 408.74 | 435.35 | 268.87 | 395.5 | 158.52 | |||||
EBIT / Interest Expense | -10.52 | -11.07 | -10.59 | -8.56 | -6.89 | |||||
EBITDA / Interest Expense | -10.25 | -10.73 | -10.15 | -8.24 | -6.49 | |||||
(EBITDA - Capex) / Interest Expense | -11.45 | -11.21 | -10.8 | -8.37 | -6.66 | |||||
Total Debt / EBITDA | -0.74 | -0.4 | -0.86 | -1.05 | -1.15 | |||||
Net Debt / EBITDA | -0.44 | -0.3 | -0.82 | -1.02 | -1.1 | |||||
Total Debt / (EBITDA - Capex) | -0.66 | -0.39 | -0.8 | -1.04 | -1.12 | |||||
Net Debt / (EBITDA - Capex) | -0.4 | -0.28 | -0.77 | -1 | -1.07 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -22.15 | 67.46 | 14.8 | -28.47 | -0.29 | |||||
Gross Profit, 1 Yr. Growth % | -103.11 | 75.25 | -23.74 | 29.88 | -18.2 | |||||
EBITDA, 1 Yr. Growth % | -39.46 | 25.87 | -18.12 | 19.97 | -10.68 | |||||
EBITA, 1 Yr. Growth % | -39.15 | 27.47 | -17.38 | 19.82 | -10.16 | |||||
EBIT, 1 Yr. Growth % | -39.15 | 27.47 | -17.38 | 19.82 | -9.91 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -133.81 | -158.64 | -40.4 | 33.83 | -28.19 | |||||
Net Income, 1 Yr. Growth % | -133.81 | -158.64 | -40.4 | 33.83 | -28.19 | |||||
Normalized Net Income, 1 Yr. Growth % | -133.94 | -157.08 | -44.11 | 38.22 | -15.74 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -91.82 | 73.04 | -41.97 | 16.67 | -39.71 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 36.38 | -1.41 | 9.3 | -5.02 | 5.99 | |||||
Total Assets, 1 Yr. Growth % | 22.07 | -22 | -11.04 | -4.08 | 204.14 | |||||
Tangible Book Value, 1 Yr. Growth % | -65.49 | 3.27 | -47.94 | 42.42 | 18.35 | |||||
Common Equity, 1 Yr. Growth % | -65.84 | 3.32 | -48.66 | 43.66 | -36.2 | |||||
Cash From Operations, 1 Yr. Growth % | 19.34 | 37.8 | 1.63 | 6.3 | -21.49 | |||||
Capital Expenditures, 1 Yr. Growth % | -9 | -51.75 | 18.44 | -70.5 | 48.32 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -183.03 | -82.02 | 162.64 | -74.44 | -20.67 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -182.18 | -82.34 | 166.69 | -76.28 | -26.64 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -35.42 | 14.18 | 38.65 | -9.38 | -15.55 | |||||
Gross Profit, 2 Yr. CAGR % | -70.69 | 2.27 | 15.61 | -0.48 | 3.07 | |||||
EBITDA, 2 Yr. CAGR % | 36.87 | -12.71 | 1.52 | -0.89 | 3.52 | |||||
EBITA, 2 Yr. CAGR % | 37.25 | -11.93 | 2.63 | -0.5 | 3.75 | |||||
EBIT, 2 Yr. CAGR % | 37.25 | -11.93 | 2.63 | -0.5 | 3.89 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 193.37 | -55.48 | -40.88 | -10.69 | -1.97 | |||||
Net Income, 2 Yr. CAGR % | 193.37 | -55.48 | -40.88 | -10.69 | -1.97 | |||||
Normalized Net Income, 2 Yr. CAGR % | 208.23 | -55.98 | -43.52 | -13.67 | 7.92 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 22.22 | -62.38 | 0.21 | -17.72 | -16.13 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 73.12 | 15.96 | 3.81 | 1.89 | 0.33 | |||||
Total Assets, 2 Yr. CAGR % | 94.25 | -2.42 | -16.7 | -7.63 | 70.8 | |||||
Tangible Book Value, 2 Yr. CAGR % | 67.17 | -40.3 | -26.68 | -13.89 | 29.83 | |||||
Common Equity, 2 Yr. CAGR % | 65.89 | -40.59 | -27.17 | -14.12 | -4.27 | |||||
Cash From Operations, 2 Yr. CAGR % | 9.64 | 28.24 | 18.34 | 3.94 | -8.65 | |||||
Capital Expenditures, 2 Yr. CAGR % | 308.76 | -33.74 | -24.41 | -40.89 | -33.85 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 177.55 | -61.36 | -33.85 | -18.07 | -54.97 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 178.83 | -61.9 | -34.01 | -20.46 | -58.28 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 34.61 | -11.28 | 14.38 | 11.2 | -6.45 | |||||
Gross Profit, 3 Yr. CAGR % | -61.6 | 42.48 | -7.26 | 20.18 | -6.78 | |||||
EBITDA, 3 Yr. CAGR % | 6.41 | 33.1 | -14.55 | 7.33 | -4.26 | |||||
EBITA, 3 Yr. CAGR % | 5.6 | 33.91 | -13.78 | 8.06 | -3.83 | |||||
EBIT, 3 Yr. CAGR % | 5.6 | 33.91 | -13.78 | 8.06 | -3.74 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 71.05 | 71.53 | -50.93 | -22.38 | -16.95 | |||||
Net Income, 3 Yr. CAGR % | 71.05 | 71.53 | -50.93 | -22.38 | -16.95 | |||||
Normalized Net Income, 3 Yr. CAGR % | 66.06 | 75.69 | -52.34 | -24.79 | -14.37 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -21.12 | 37.24 | -56.53 | 5.42 | -25.82 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 469.19 | 43.5 | 13.69 | 0.78 | 3.24 | |||||
Total Assets, 3 Yr. CAGR % | 17.64 | 43.31 | -5.39 | -12.69 | 37.42 | |||||
Tangible Book Value, 3 Yr. CAGR % | 38.73 | 42.37 | -42.97 | -8.52 | -4.26 | |||||
Common Equity, 3 Yr. CAGR % | 38.02 | 41.67 | -43.41 | -8.66 | -22.22 | |||||
Cash From Operations, 3 Yr. CAGR % | 3.46 | 18.32 | 18.67 | 14.18 | -5.34 | |||||
Capital Expenditures, 3 Yr. CAGR % | 214.7 | 100.51 | -19.59 | -44.76 | -19.68 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 130.37 | 11.47 | -28.65 | -51.82 | -18.95 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 128.3 | 11.14 | -29 | -53.08 | -22.58 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.04 | 38.02 | 36.21 | -10.53 | 1.31 | |||||
Gross Profit, 5 Yr. CAGR % | -55.78 | 0.39 | 7.77 | 23.43 | -3.26 | |||||
EBITDA, 5 Yr. CAGR % | -7.91 | 3.98 | 4.43 | 18.29 | -7.73 | |||||
EBITA, 5 Yr. CAGR % | -7.84 | 4.2 | 4.4 | 18.91 | -7.15 | |||||
EBIT, 5 Yr. CAGR % | -7.84 | 4.2 | 4.4 | 18.91 | -7.1 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 17.43 | 7.51 | 11.83 | 32.12 | -35.28 | |||||
Net Income, 5 Yr. CAGR % | 17.43 | 7.51 | 11.83 | 32.12 | -35.28 | |||||
Normalized Net Income, 5 Yr. CAGR % | 20.04 | 11.92 | 7.87 | 32.22 | -34.38 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -40.07 | -19.53 | -13.19 | 11.84 | -43.46 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -15 | -16.19 | 188.17 | 25.13 | 8.15 | |||||
Total Assets, 5 Yr. CAGR % | -5.36 | -8.53 | 2.47 | 20.22 | 19.83 | |||||
Tangible Book Value, 5 Yr. CAGR % | 36.57 | 14.07 | 7.5 | 16.43 | -20.75 | |||||
Common Equity, 5 Yr. CAGR % | 36.15 | 13.73 | 6.88 | 15.96 | -30.17 | |||||
Cash From Operations, 5 Yr. CAGR % | -7.2 | 7.66 | 9.17 | 12.35 | 6.88 | |||||
Capital Expenditures, 5 Yr. CAGR % | 4.02 | 225.03 | 77.88 | 23.01 | -25.63 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 42.2 | 22.84 | 39.85 | -2.94 | -40.65 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 43.08 | 25.27 | 38.97 | -4.29 | -42.6 |
Select your edition
All financial news and data tailored to specific country editions
















